Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06094712 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects
A Phase 1 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06094712 is a Phase 1 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT06094712, a Phase 1 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
A study designed to characterize the pharmacokinetic (PK) profile of CORT125134 following a single 150-mg oral dose of the Phase 2 capsule formulation of CORT125134 in 8 healthy male subjects.
Interventions
- DRUG CORT125134
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-04-07 |
| Est. Completion | 2016-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06094712
The ClinicalTrials.gov registry entry for NCT06094712 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CORT125134 is the first listed.
NCT06094712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06094712 about?
NCT06094712 is a clinical study titled "A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects". A study designed to characterize the pharmacokinetic (PK) profile of CORT125134 following a single 150-mg oral dose of the Phase 2 capsule formulation of CORT125134 in 8 healthy male subjects.
What is the current status of trial NCT06094712?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-04-07. Estimated completion is 2016-04-27.
What interventions are being tested in trial NCT06094712?
The interventions under investigation include: CORT125134 (DRUG).
Who is sponsoring clinical trial NCT06094712?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.